Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence

By afschroeder • June 11, 2025

Sugumar K, Alabd A, Alabd A, Hue JJ, Lyons J, Fields S, Wainberg Z, Zheng L, Coogle B, Kasi A, Grewal N, Kindler HL, Starr J, Sama AR, Winter JM. Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence. Oncotarget. 2025 Jun 10;16:427-442. doi: 10.18632/oncotarget.28739. PMID: 40492845; PMCID: PMC12151408.

Tags: DGSOM Student, exceptional responders, Hematology/Oncology, immunotherapy, microsatellite instability, Pancreatic adenocarcinoma, Publications, survival

Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer

Karunanandaa K, Knoche EM, Montgomery RB, Pickett C, Doherty J, Gruber J, Raychaudhuri R, Eaton D, Garraway IP, Rettig M, Maxwell KN, Schoen MW. Tumor[...]

B Cell Receptor’s function in virus entry: Anti-SARS-CoV-2 B cell receptors can mediate viral entry in an ACE2-independent mechanism

Larios R, Hossain MB, Brown R, Jeyachandran AV, Abu AE, Zaiss AK, Ramirez CM, Kamata M, Cole S, Wu TT, Dorshkind K, Arumugaswami V, Morizono[...]

Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

Landon BV, Boland JL, Wahner Hendrickson AE, Armstrong DK, Winterhoff B, Wehr J, Annapragada AV, Cherry C, Balan A, Kaleka G, Velculescu VE, Baylin SB,[...]